Inhibrx Biosciences, Inc.

NasdaqGS INBX

Inhibrx Biosciences, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 106.36

Inhibrx Biosciences, Inc. Price to Sales Ratio (P/S) is 106.36 on January 14, 2025, a -13.86% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.
  • Inhibrx Biosciences, Inc. 52-week high Price to Sales Ratio (P/S) is 148.95 on January 06, 2025, which is 40.05% above the current Price to Sales Ratio (P/S).
  • Inhibrx Biosciences, Inc. 52-week low Price to Sales Ratio (P/S) is 80.71 on August 09, 2024, which is -24.11% below the current Price to Sales Ratio (P/S).
  • Inhibrx Biosciences, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 114.63.
Key data
Date Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield
Market news
Loading...
NasdaqGS: INBX

Inhibrx Biosciences, Inc.

CEO Mr. Mark Paul Lappe
IPO Date June 4, 2024
Location United States
Headquarters 11025 North Torrey Pines Road
Employees 166
Sector Health Care
Industries
Description

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.

Similar companies

MRUS

Merus N.V.

USD 39.01

-3.56%

OPT

Opthea Limited

USD 3.82

6.70%

GLUE

Monte Rosa Therapeutics, Inc.

USD 5.56

-1.77%

LRMR

Larimar Therapeutics, Inc.

USD 3.29

-5.46%

MLYS

Mineralys Therapeutics, Inc.

USD 9.12

-2.56%

PTGX

Protagonist Therapeutics, Inc.

USD 36.67

-1.26%

CELC

Celcuity Inc.

USD 10.53

-2.95%

CRNX

Crinetics Pharmaceuticals, Inc.

USD 35.62

-8.62%

STOK

Stoke Therapeutics, Inc.

USD 8.68

-2.69%

VRDN

Viridian Therapeutics, Inc.

USD 16.86

-5.12%

DSGN

Design Therapeutics, Inc.

USD 4.02

-2.19%

ELVN

Enliven Therapeutics, Inc.

USD 20.46

-7.29%

ANEB

Anebulo Pharmaceuticals, Inc.

USD 1.60

5.96%

HOWL

Werewolf Therapeutics, Inc.

USD 1.35

0.00%

IKNA

Ikena Oncology, Inc.

USD 1.51

-1.95%

StockViz Staff

January 15, 2025

Any question? Send us an email